SIMILARITIES AND DIFFERENCES BETWEEN FIVE EUROPEAN DRUG REIMBURSEMENT SYSTEMS
Authors:
- Margreet FrankenMFMargreet Franken
- Maïté le PolainMPMaïté le Polain
- Irina CleemputICIrina Cleemput
- Marc KoopmanschapMKMarc Koopmanschap
- 19 September 2012
- journal article
- research article
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 28 (4) , 349-357
Abstract
Objectives: The aim of our study is to compare five European drug reimbursement systems, describe similarities and differences, and obtain insight into their strengths and weaknesses and formulate policy recommendations.Methods: We used the analytical Hutton Framework to assess in detail drug reimbursement systems in Austria, Belgium, France, the Netherlands, and Sweden. We investigated policy documents, explored literature, and conducted fifty-seven interviews with relevant stakeholders.Results: All systems aim to balance three main objectives: system sustainability, equity and quality of care. System impact, however, is mainly assessed by drug expenditure. A national reimbursement agency evaluates reimbursement requests on a case-by-case basis. The minister has discretionary power to alter the reimbursement advice in Belgium, France, and the Netherlands. All systems make efforts to increase transparency in the decision-making process but none uses formal hierarchical reimbursement criteria nor applies a cost-effectiveness threshold value. Policies to deal with uncertainty vary: financial risk-sharing by price/volume contracts (France, Belgium) versus coverage with evidence development (Sweden, the Netherlands). Although case-by-case revisions are embedded in some systems for specific groups of drugs, systematic (group) revisions are limited.Conclusions: As shared strengths, all systems have clear objectives reflected in reimbursement criteria and all are prepared to pay for drugs with sufficient added value. However, all systems could improve the transparency of the decision-making process; especially appraisal lacks transparency. Systems could increase the use of (systematic) revisions and could make better use of HTA (among others cost-effectiveness) to obtain value for money and ensure system sustainability.Keywords
This publication has 20 references indexed in Scilit:
- International Comparison of Comparative Effectiveness Research in Five JurisdictionsPharmacoEconomics, 2010
- Reimbursement of pharmaceuticals: reference pricing versus health technology assessmentThe European Journal of Health Economics, 2010
- Registries for Robust EvidenceJAMA, 2009
- Conditional reimbursement within the Dutch drug policyHealth Policy, 2007
- Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force ReportValue in Health, 2007
- Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysisHealth Policy, 2007
- The Increasingly Complex Fourth Hurdle for PharmaceuticalsPharmacoEconomics, 2007
- Reimbursement decisions in health policy—extending our understanding of the elements of decision-makingHealth Policy, 2005
- Drug reimbursement in Finland—a case of explicit prioritising in special categoriesHealth Policy, 2003
- What criteria for pharmaceuticals reimbursement?The European Journal of Health Economics, 2003